| Title |
Cathepsin B Improves ß-Amyloidosis and Learning and Memory in Models of Alzheimer’s Disease
|
|---|---|
| Published in |
Journal of Neuroimmune Pharmacology, December 2016
|
| DOI | 10.1007/s11481-016-9721-6 |
| Pubmed ID | |
| Authors |
Christine M Embury, Bhagyalaxmi Dyavarshetty, Yaman Lu, Jayme L Wiederin, Pawel Ciborowski, Howard E Gendelman, Tomomi Kiyota |
| Abstract |
Amyloid-ß (Aß) precursor protein (APP) metabolism engages neuronal endolysosomal pathways for Aß processing and secretion. In Alzheimer's disease (AD), dysregulation of APP leads to excess Aß and neuronal dysfunction; suggesting that neuronal APP/Aß trafficking can be targeted for therapeutic gain. Cathepsin B (CatB) is a lysosomal cysteine protease that can lower Aß levels. However, whether CatB-modulation of Aß improves learning and memory function deficits in AD is not known. To this end, progenitor neurons were infected with recombinant adenovirus expressing CatB and recovered cell lysates subjected to proteomic analyses. The results demonstrated Lamp1 deregulation and linkages between CatB and the neuronal phagosome network. Hippocampal injections of adeno-associated virus expressing CatB reduced Aß levels, increased Lamp1 and improved learning and memory. The findings were associated with the emergence of c-fos + cells. The results support the idea that CatB can speed Aß metabolism through lysosomal pathways and as such reduce AD-associated memory deficits. |
Mendeley readers
The data shown below were compiled from readership statistics for 67 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 67 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 10 | 15% |
| Other | 9 | 13% |
| Researcher | 8 | 12% |
| Student > Master | 7 | 10% |
| Student > Doctoral Student | 5 | 7% |
| Other | 5 | 7% |
| Unknown | 23 | 34% |
| Readers by discipline | Count | As % |
|---|---|---|
| Neuroscience | 13 | 19% |
| Biochemistry, Genetics and Molecular Biology | 10 | 15% |
| Agricultural and Biological Sciences | 6 | 9% |
| Medicine and Dentistry | 5 | 7% |
| Engineering | 2 | 3% |
| Other | 5 | 7% |
| Unknown | 26 | 39% |
Attention Score in Context
This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 April 2021.
All research outputs
#3,258,546
of 24,532,617 outputs
Outputs from Journal of Neuroimmune Pharmacology
#87
of 591 outputs
Outputs of similar age
#62,808
of 429,968 outputs
Outputs of similar age from Journal of Neuroimmune Pharmacology
#3
of 5 outputs
Altmetric has tracked 24,532,617 research outputs across all sources so far. Compared to these this one has done well and is in the 86th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 591 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.6. This one has done well, scoring higher than 84% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 429,968 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.
We're also able to compare this research output to 5 others from the same source and published within six weeks on either side of this one. This one has scored higher than 2 of them.